Study the effect of CAPRIDIN in the metabolic treatment of drug-resistant epilepsy
Phase 1
Recruiting
- Conditions
- Drug-resistant temporal lobe epilepsy.Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizuresG40.2
- Registration Number
- IRCT20170315033086N11
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients with drug-resistant temporal lobe epilepsy
Taking up to 3 or more standard anticonvulsants
Having at least 3 seizures per month.
Exclusion Criteria
Failure to adhere to dietary guidelines.
Metabolic syndrome
Pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expression level of ecto-5-nucleotidase (CD73) in the patients brain tissue. Timepoint: Two months after taking CAPRIDIN and then brain tissue sampling after surgery. Method of measurement: Using Real-Time PCR and Western blot techniques.;Expression level of adenosine kinase in the patients brain tissue. Timepoint: Two months after taking CAPRIDIN and then brain tissue sampling after surgery. Method of measurement: Using Real-Time PCR and Western blot techniques.
- Secondary Outcome Measures
Name Time Method